Juno Therapeutics halts development of high-profile cancer drug; shares drop | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 2 March, 2017 by The TZ Newswire Staff

Juno Therapeutics halts development of high-profile cancer drug; shares drop

The drug, known as JCAR015, was being tested in adults with relapsed acute lymphoblastic leukemia.

See also
- Next Article Here’s why AMD shares, up more than 500% in past year, are tanking today
- Previous Article Here’s How Buffett Could End Up Owning a Piece of Pandora
Editorial Calender

March 2017

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

« Feb Apr »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar